# OnCo record equecabtagene-autoleucel (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/equecabtagene-autoleucel/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "equecabtagene-autoleucel" ;
  schema:name "Equecabtagene autoleucel"@en ;
  schema:description "Equecabtagene autoleucel is a BCMA CAR-T from IASO Bio and Innovent, approved in China in June 2023 for multiple myeloma that has returned after at least three lines of treatment. In the FUMANBA-1 trial about 96% of infused patients responded, most with deep minimal-residual-disease-negative remissions and few severe cytokine release reactions; it competes with cilta-cel and zevor-cel in China."@en ;
  schema:url <https://onco.cc/drugs/equecabtagene-autoleucel/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.iasobio.com/>, <https://doi.org/10.1001/jamaoncol.2024.4879>, <https://doi.org/10.1007/s40291-023-00673-y> ;
  onco:status "approved" ;
  onco:tag "china" ;
  onco:modality "Cell therapy (autologous BCMA CAR-T, fully human binder)" ;
  schema:alternateName "Fucaso" ;
  onco:approval "China 2023: Relapsed or refractory multiple myeloma after three or more lines including a proteasome inhibitor and an immunomodulatory agent" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/car-t/> ;
  onco:targets <https://onco.cc/targets/bcma/> ;
  onco:companies <https://onco.cc/companies/iaso-bio/>, <https://onco.cc/companies/innovent/> ;
  onco:institutions <https://onco.cc/institutions/tongji-hospital-wuhan/> ;
  onco:trials <https://onco.cc/trials/fumanba-1/>, <https://onco.cc/trials/nct06464991/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-li-jama-oncol/>, <https://onco.cc/key-papers/paper-keam-mol-diagn-ther/> .